Insmed Ebitda Over Time
| INSM Stock | USD 75.88 0.20 0.26% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Insmed Performance and Insmed Correlation. Insmed |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insmed. If investors know Insmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.55) | Revenue Per Share 2.206 | Quarterly Revenue Growth 0.182 | Return On Assets (0.26) | Return On Equity (8.91) |
The market value of Insmed Inc is measured differently than its book value, which is the value of Insmed that is recorded on the company's balance sheet. Investors also form their own opinion of Insmed's value that differs from its market value or its book value, called intrinsic value, which is Insmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insmed's market value can be influenced by many factors that don't directly affect Insmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Ebitda Analysis
Compare Insmed Inc and related stocks such as Ascendis Pharma AS, Apellis Pharmaceuticals, and BeiGene Ebitda Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASND | 1.9 M | 1.9 M | 1.9 M | 5.7 M | (11.5 M) | (41.3 M) | (72.1 M) | (109.9 M) | (150.2 M) | (217 M) | (328.9 M) | (423.7 M) | (556 M) | (411.2 M) | (390.6 M) |
| APLS | (4 M) | (4 M) | (4 M) | (4 M) | (11.3 M) | 6.4 M | (27.3 M) | (50.6 M) | (125.1 M) | (282.8 M) | (312.2 M) | (731.3 M) | (617.4 M) | (495.2 M) | (470.5 M) |
| BGNE | (2.7 M) | (2.7 M) | (2.7 M) | (2.7 M) | (13.2 M) | (54.3 M) | (117.3 M) | (86.1 M) | (679.2 M) | (958.6 M) | (1.6 B) | (1.4 B) | (1.7 B) | (1.1 B) | (1.2 B) |
| AKRO | (81.7 M) | (81.7 M) | (81.7 M) | (81.7 M) | (81.7 M) | (81.7 M) | (81.7 M) | (81.7 M) | (81.7 M) | (45.7 M) | (80.1 M) | (100.8 M) | (111 M) | (148.6 M) | (156.1 M) |
| BPMC | (20.3 M) | (20.3 M) | (20.3 M) | (20.3 M) | (39.2 M) | (52.1 M) | (72 M) | (147.9 M) | (236.6 M) | (361.3 M) | 308.7 M | (628.3 M) | (515.4 M) | (470.4 M) | (446.8 M) |
| RNA | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (10.1 M) | (17 M) | (43.9 M) | (117.4 M) | (177.5 M) | (233.5 M) | (221.8 M) |
| RVMD | (29.8 M) | (29.8 M) | (29.8 M) | (29.8 M) | (29.8 M) | (29.8 M) | (29.8 M) | (29.8 M) | (39.9 M) | (48.6 M) | (101.9 M) | (179.7 M) | (239.5 M) | (430.6 M) | (409.1 M) |
| DAWN | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (43.7 M) | (72.5 M) | (146.4 M) | (206.1 M) | (195.8 M) |
| SWTX | (18.5 M) | (18.5 M) | (18.5 M) | (18.5 M) | (18.5 M) | (18.5 M) | (18.5 M) | (18.5 M) | (18.5 M) | (59 M) | (46 M) | (173 M) | (279.9 M) | (341.3 M) | (324.3 M) |
| KROS | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (9.8 M) | (44.9 M) | (56.4 M) | (103.1 M) | (152.2 M) | (144.6 M) |
| JANX | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (4.8 M) | (32.8 M) | (66.2 M) | (71 M) | (67.5 M) |
| FENC | (1.6 M) | (3.4 M) | (3.6 M) | (1.9 M) | (3.6 M) | (3.1 M) | (3 M) | (6.8 M) | (10.6 M) | (12.9 M) | (17.9 M) | (123 K) | (22.6 M) | (12.4 M) | (11.7 M) |
| EWTX | (9.8 M) | (9.8 M) | (9.8 M) | (9.8 M) | (9.8 M) | (9.8 M) | (9.8 M) | (9.8 M) | (9.8 M) | (9.8 M) | (17 M) | (42.9 M) | (21.5 M) | (112.8 M) | (107.2 M) |
| HRMY | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (41.3 M) | (142.7 M) | 1.5 M | 106.4 M | 143.6 M | 221.5 M | 232.6 M |
| HALO | (39.8 K) | (19.8 M) | (52.5 M) | (79.2 M) | (61.3 M) | (25.8 M) | (80.8 M) | 83.2 M | (66.9 M) | (63.5 M) | 147.5 M | 278.9 M | 315.5 M | 451.9 M | 474.5 M |
| AGIO | (15.8 M) | (15.8 M) | (21.8 M) | (37.4 M) | (52.8 M) | (115.4 M) | (195.3 M) | (314.4 M) | (355.3 M) | (418.2 M) | (326.1 M) | (337.7 M) | (380.5 M) | (384.9 M) | (365.6 M) |
| RARE | (6.5 M) | (6.5 M) | (16 M) | (34.6 M) | (56.1 M) | (146.4 M) | (244.6 M) | (323.1 M) | (541.7 M) | (411.7 M) | (139.8 M) | (410.3 M) | (640.5 M) | (516.5 M) | (490.6 M) |
Insmed Inc and related stocks such as Ascendis Pharma AS, Apellis Pharmaceuticals, and BeiGene Ebitda description
My Equities
My Current Equities and Potential Positions
| Insmed Inc | INSM |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | New Jersey; U.S.A |
| Exchange | NASDAQ Exchange |
USD 75.88
Check out Insmed Performance and Insmed Correlation. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Insmed technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.